Mizuho Cuts Assembly Biosciences (NASDAQ:ASMB) Price Target to $45.00

Assembly Biosciences (NASDAQ:ASMB) had its price objective trimmed by Mizuho from $53.00 to $45.00 in a research report released on Tuesday,Benzinga reports. The brokerage currently has an outperform rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued reports about the company. Wall Street Zen cut Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. Guggenheim reiterated a “buy” rating and set a $43.00 price target on shares of Assembly Biosciences in a research note on Thursday, May 28th. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Assembly Biosciences in a research note on Tuesday, August 18th. Zacks Research raised shares of Assembly Biosciences from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 20th. Finally, UBS Group started coverage on shares of Assembly Biosciences in a research note on Tuesday. They issued a “buy” rating and a $52.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Assembly Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.60.

Assembly Biosciences Stock Down 1.6%

ASMB stock opened at $36.13 on Tuesday. Assembly Biosciences has a twelve month low of $20.23 and a twelve month high of $39.71. The company has a market cap of $735.61 million, a PE ratio of 35.42 and a beta of 1.13. The business’s 50-day simple moving average is $29.01 and its 200 day simple moving average is $28.14.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.52. Assembly Biosciences had a negative return on equity of 0.02% and a negative net margin of 0.06%.The firm had revenue of $13.37 million during the quarter, compared to analysts’ expectations of $8.60 million. On average, equities research analysts anticipate that Assembly Biosciences will post 2.28 EPS for the current year.

Institutional Investors Weigh In On Assembly Biosciences

Large investors have recently bought and sold shares of the business. RA Capital Management L.P. bought a new stake in shares of Assembly Biosciences during the third quarter worth $26,122,000. Janus Henderson Group PLC lifted its position in Assembly Biosciences by 1.4% during the 1st quarter. Janus Henderson Group PLC now owns 849,309 shares of the biopharmaceutical company’s stock valued at $23,479,000 after purchasing an additional 11,384 shares during the period. Paradigm Biocapital Advisors LP bought a new position in shares of Assembly Biosciences in the 4th quarter valued at about $22,625,000. Vanguard Group Inc. boosted its stake in shares of Assembly Biosciences by 97.8% in the 3rd quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock valued at $12,854,000 after purchasing an additional 248,287 shares during the last quarter. Finally, Seven Fleet Capital Management LP grew its position in shares of Assembly Biosciences by 671.5% during the 2nd quarter. Seven Fleet Capital Management LP now owns 433,147 shares of the biopharmaceutical company’s stock worth $11,903,000 after buying an additional 377,000 shares during the period. 19.92% of the stock is currently owned by institutional investors.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.